FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL								
OMB Number:	3235-0104							
Estimated average burden								
hours per response:	0.5							

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

D 1 1 D 1 1			2. Date of Event Requirement (Month/Dath/Dath/Dath/Dath/Dath/Dath/Dath/Da			Name and Ticker or Trading Symb Medicine, Inc. [PRME]	ool					
(Last) C/O PRIME MED 21 ERIE STREET (Street) CAMBRIDGE (City)	(First) ICINE, INC. MA (State)	(Middle) 02139 (Zip)				nship of Reporting Person(s) to Iss applicable) Director Officer (give title below) Chief Business Of	10% Owner Other (specify	below) 6. Ir	ndividual or Joint/Gro	f Original Filed (Month/Day/Year) up Filing (Check Applicable Line) One Reporting Person More than One Reporting Person		
Table I - Non-Derivative Securities Beneficially Owned												
			2. Amount Owned (Ins	of Securities Beneficially str. 4)	3. Ownership For Direct (D) or Incomplete (Instr. 5)		4. Nature of Indirect Beneficial Ownership (Instr. 5)					
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)												
1. Title of Derivative Security (Instr. 4)			Expiration	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Deri Security (Instr. 4)		4. Conversion or Exercise Price of	ise or Indirect (I) `	6. Nature of Indirect Beneficial Ownership (Instr. 5)		
		Date Exercisable	Expiration Date	Title		Amount or Number of Shares		(Instr. 5)				
Stock Option (right	to buy)		(1)	08/04/2032		Common Stock	167,267	7.96	D			
Stock Option (right to buy)			(2)	08/04/2032		Common Stock	19,300	7.96	D			

Explanation of Responses:

- 1. 25% of the shares underlying this option shall vest and become exercisable on July 1, 2023, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date
- 2. The shares underlying this option shall vest in full upon the successful completion of the Issuer's initial public offering

Remarks:

Exhibit 24 - Power of Attorney

/s/ Carman Alenson attorney-in-fact

10/19/2022

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

 ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

LIMITED POWER OF ATTORNEY

The undersigned hereby constitutes and appoints each of Keith Gottesdiener, Carman Alenson and Karen Brown of Prime Medicine, Inc., a Delaware

- 1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of the Company, from time
- (2) do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to complete and execute any
- take any other action of any type whatsoever in connection with the foregoing that, in the opinion of such attorney-in-fact, may be

 The undersigned hereby grants to each such attorney-in-fact, acting singly, full power and authority to do and perform any and every act as

 This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file such forms with respect to

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of October 19, 2022.

/s/ Richard Brudnick Signature

Richard Brudnick Print Name